Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 1:16 PM ET

Pharmaceuticals

Company Overview of Tocagen Inc.

Company Overview

Tocagen Inc., a biopharmaceutical company, discovers, develops, and commercializes products for the treatment of cancer. The company focuses on developing a treatment for High Grade Glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; and Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more distant metastatic cancer cells. The company was founded in 2007 and...

3030 Bunker Hill Street

Suite 230

San Diego, CA 92109

United States

Founded in 2007

Phone:

858-412-8400

Fax:

858-412-8499

Key Executives for Tocagen Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 62
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Age: 67
Co-Founder, Executive Vice President of Corporate Development and Director
Age: 64
Chief Financial Officer, Executive Vice President and Director
Age: 64
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2015.

Tocagen Inc. Key Developments

FDA Grants Orphan Drug Designation for Tocagen's Toca 511 & Toca FC

Tocagen Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. As previously announced, the investigational drug was granted FDA Fast Track designation for the treatment of recurrent high-grade glioma, which includes glioblastoma and anaplastic astrocytoma, and is poised to move into a pivotal clinical trial later this 2015. Toca 511 & Toca FC is an investigational treatment that is designed to program cancer cells to convert the prodrug 5-FC into the anticancer drug 5-FU, killing tumor cells and leading to activation of the immune system through a combination of mechanisms. Toca 511 is a retroviral replicating vector (RRV) that selectively delivers a gene for the enzyme cytosine deaminase to the tumor. Patients then take oral cycles of Toca FC, a novel formulation of an antifungal drug, which is converted within infected cancer cells into the FDA-approved anticancer drug, 5-fluorouracil (5 FU). As a result, in addition to direct 5-FU mediated killing the immune system is activated to recognize and kill cancer cells, leaving healthy cells unharmed. Immune activation locally in the tumor occurs through a combination of mechanisms that together break the barrier of immune tolerance and may lead to durable tumor response.

FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma

-? Tocagen Inc. [1], a clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead iTocagen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma. This treatment will enter a registrational study called Toca 5 later this year in patients with recurrent glioblastoma or anaplastic astrocytoma. Toca 511 & Toca FC is an immuno-oncology therapy that will advance into a registrational trial in 2015 in patients with recurrent glioblastoma or anaplastic astrocytoma. Toca 511 & Toca FC are designed to selectively transform cancer cells so they produce a chemotherapy drug within the tumor while also activating the immune system against the tumor with local and systemic benefits. Toca 511 is a retroviral replicating vector (RRV) that selectively delivers a gene for the enzyme cytosine deaminase to the cancer cells. The patient then takes oral cycles of Toca FC, a novel formulation of an antifungal drug, which is converted into the FDA-approved chemotherapy drug, 5-fluorouracil (5 FU). As a result, infected cancer cells are selectively killed, subsequently activating the immune system to recognize cancer cells while leaving healthy cells unharmed. Immune activation locally in the tumor occurs through a combination of mechanisms which leads to breaking of immune tolerance and activation of the immune system selectively against the cancer cells.

Tocagen Inc. Appoints Asha Das as Vice President of Clinical Development and Medical Affairs

Tocagen Inc. announced Asha Das, M.D. has been named vice president of clinical development and medical affairs. Prior to joining she held positions of increasing responsibility at Genentech, including activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to PD-L1.

Similar Private Companies By Industry

Company Name Region
AMRI Rensselaer, Inc. United States
Pepgen Corporation United States
VRN Veterinarian Recommended Nutriceuticals, LLC United States
Synergos LLC United States
Viamet Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tocagen Inc., please visit www.tocagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.